Objectives: To investigate the b-lactamase background of ertapenem non-susceptible isolates for the presence of the most commonly detected carbapenemase genes, bla KPC , bla OXA-48 and bla VIM , and the newly described bla NDM-1 .
Introduction
Carbapenems are often the most effective antibiotics used against multidrug-resistant (MDR) Enterobacteriaceae. For many years these potent b-lactams were highly effective against bacteria that exhibited resistance to extended-spectrum cephalosporins (e.g. ceftazidime and cefepime), including extended-spectrum b-lactamase (ESBL) and AmpC producers. 1 However, as carbapenemases began to emerge worldwide, the effectiveness of this 'last-line' antibiotic class was challenged. 2 The first major test for carbapenem antibiotics came with the sporadic reports of metallo-b-lactamases found in Aeromonas spp., Stenotrophomonas maltophilia and Pseudomonas spp. 3 Metallo-b-lactamases were also discovered in Bacteroides fragilis and Bacillus spp., but these resistant phenotypes were uncommon. 4, 5 A greater challenge arose from the widespread dissemination of serine carbapenemases of the KPC family.
6 -10 KPC b-lactamases are currently found in numerous genera of bacteria and have spread worldwide. Unfortunately, the recently reported metallo-b-lactamase NDM-1 (New Delhi metallob-lactamase) is now emerging as a new mechanism by which bacteria manifest resistance to carbapenems. 11 The rapid spread of NDM-1 is causing major concern in the clinical microbiology community. 12 -14 The impact of these resistance determinants on the outcome of patients with hospital-and community-acquired infections needs to be monitored very closely.
To halt the spread of carbapenem resistance, rapid detection methods are needed. As infection control and therapeutic decisions need to be implemented quickly (in many cases ,48 h after admission to hospital), there is a pressing need to rapidly detect these determinants. Presently, the most common carbapenemases reported in Enterobacteriaceae include KPC, OXA-48 and the VIM metallo-b-lactamase. 15 Increasing vigilance is also required to detect the NDM-1 metallo-b-lactamase, especially as the genetic backgrounds of strains harbouring this bla gene tend to be complex.
In this study, we examined a collection of ertapenem nonsusceptible Enterobacteriaceae isolates from five continents obtained as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART) using molecular methods for rapid and accurate detection of b-lactamase genes. Our results highlight the complexity and diversity of the genetic background of these highly resistant isolates and point to the important role microarray testing plays in defining the molecular basis of these isolates.
Materials and methods

Bacterial isolates
Two hundred and thirty-five isolates of Enterobacteriaceae from intra-abdominal infections collected as part of the SMART study were selected by their reduced susceptibility to ertapenem according to the updated CLSI breakpoints (MICs ≥0.5 mg/L). 16, 17 All isolates were nonduplicates from 2009 and originated from a variety of intra-abdominal infections. Isolates were collected from Europe (28%, 20 sites), Asia (28%, 27 sites), North America (21%, 20 sites), Latin America (13%, 12 sites), the South Pacific (7%, 6 sites) and the Middle East (3%, 2 sites). A large proportion of isolates from Asia originated from India (68%, 8 sites).
Susceptibility testing
MICs were determined using dehydrated broth microdilution MicroScan panels (Siemens Healthcare Diagnostics, IL, USA) or in-house panels (colistin) following 2010 CLSI and manufacturer's guidelines. Susceptibility data were interpreted using CLSI guidelines 16 or European Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpoints (colistin) and FDA breakpoints (tigecycline) where CLSI breakpoints are not defined.
Molecular detection
Whole genomic DNA was extracted using the QIAamp DNA Mini Kit and the QIAcube instrument (Qiagen, Valencia, CA, USA) from overnight colonies grown on agar (Remel, Lenexa, KS, USA). We designed a multiplex PCR for the rapid detection of bla KPC , bla OXA-48 , bla VIM and bla NDM-1 genes. Primers used have been described previously except those for bla NDM-1 , which were designed in this study: NDM-1f 5
′ -CCGTATGAGTGATT GCGGCG-3 ′ and NDM-1r 5 ′ -GCCCAATATTATGCACCCGG-3 ′ (779 bp expected fragment). 18, 19 Klebsiella pneumoniae NCTC 13 443 was used as a positive control strain for bla NDM-1 . Total DNA was subjected to multiplex PCR using the Multiplex PCR kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. Amplicons were visualized in a 2% agarose gel containing ethidium bromide.
Carbapenemase producers were further characterized using a microarray assay (Check-MDR CT101; Check-Points, The Netherlands) 20 for detection of additional b-lactamases, bla ESBL (bla TEM , bla SHV and bla CTX-M ) and bla AmpC (bla CMY , bla DHA , bla FOX , bla MOX , bla ACC , bla MIR and bla ACT ) genes, and to confirm the presence of bla KPC and bla NDM-1 . The bla ESBL , bla KPC , bla VIM and bla NDM-1 genes were PCR-amplified and sequenced to compare them with the sequences available in the NCBI database (www.ncbi.nlm.nih.gov).
Multilocus sequence typing (MLST) was performed on carbapenemase-positive isolates of K. pneumoniae and Escherichia coli and analysed according to the Institut Pasteur MLST Databases web site (http://www.pasteur.fr/recherche/genopole/PF8/mlst). Whole DNA from Citrobacter freundii, Enterobacter cloacae and Serratia marcescens was analysed by enterobacterial repetitive intergenic consensus (ERIC)-PCR (ERIC-2 primer) and random amplification of polymorphic DNA (RAPD) (1254 and 1281 primers). 21 Fingerprints were compared visually and patterns differing by at least one amplification band were classified as different.
Results and discussion
Of the 235 isolates tested, 66 (28%) carried at least one carbapenemase gene, the most common being bla NDM-1 (50%), bla KPC (34.8%), bla VIM (10.6%) and bla OXA-48 (4.6%). Two isolates (3%) contained both bla NDM-1 and bla . Notably, all the bla NDM-1 -positive isolates were from India and comprised five different genera and species, namely K. pneumoniae, E. coli, E. cloacae, Providencia rettgeri and Morganella morganii. These findings corroborate the results of recent epidemiological studies performed in India during 2010 in which different genera carrying the bla NDM-1 gene were reported. 22, 23 The bla NDM-1 gene has also been described in Acinetobacter baumannii. 24, 25 All of our sequences were identical to the bla NDM-1 gene sequence deposited in the NCBI database (FN396876). 11 However, a new variant of this gene was recently described in A. baumannii, bla NDM-2 . 26 In addition to showing resistance to b-lactams, all isolates harbouring the bla NDM-1 gene were highly resistant to most other antibiotic classes, including aminoglycosides and fluoroquinolones. Of the 33 bla NDM-1 -harbouring isolates, 72.7% and 69.7% remained susceptible to colistin and tigecycline, respectively (Table 1) . However, three bla NDM-1 -producing strains (9.1%) were nonsusceptible to both colistin and tigecycline and included one M. morganii that exhibited intrinsic resistance and two K. pneumoniae isolates. Overall, only 51.5% of the tested isolates remained susceptible to both colistin and tigecycline. These resistance patterns present a significant clinical challenge.
Different combinations of ESBLs and AmpC were observed in bla NDM-1 -possessing strains (Table 1) . Most expressed bla ESBL and bla AmpC (18) : bla CTX-M-15 and bla CMY-2 (9); bla CTX-M-15 and bla ACT/MIR (3); bla CTX-M-15 and bla DHA (4); bla SHV-2A along with bla CTX-M-15 and bla DHA (1); and bla CTX-M-15 along with bla DHA and bla CMY-2 (1). The remaining strains possessed the following: only bla ESBL (10); bla CTX-M-15 (8) ; bla SHV-12 along with bla CTX-M-15 (2); or other combinations, namely bla CTX-M-15 , bla ACT/MIR and bla OXA-48 (2) or bla CMY-2 and bla DHA (1) or only bla DHA (1) . Remarkably, one bla ESBL -and bla AmpC -negative E. coli isolate harboured bla NDM-1 .
Molecular typing of the 18 K. pneumoniae bla NDM-1 -positive isolates resulted in 10 different sequence types (STs), including two new ones designated ST571 and ST572, respectively. ST571 was characterized by the presence of four new alleles of mdh, phoE, rpoB and tonB (designated 79, 108, 55 and 142, NDM-1 carbapenemase in Enterobacteriaceae from the SMART study respectively) while ST572 had a novel variant of tonB (new allele 143). Nine of the 18 K. pneumoniae (from two different hospitals) were identified as ST147, the remainder (obtained from four different hospitals) being identified as ST11, ST14, ST20, ST101, ST231, ST340 and ST391 (Table 1) .
The eight E. coli isolates that were positive for bla NDM-1 comprised five different STs, including one new type designated ST501, which was characterized by lack of amplification for uidA. Four isolates were identified as ST88 and the remainder as ST2, ST44 and ST471. Interestingly, the E. coli isolate carrying no additional b-lactamase genes was identified as ST88 while two other ST88 isolates from the same hospital carried bla CTX-M-15 and bla CMY-2 . Two E. cloacae from the same hospital were clonally related (cluster A by ERIC-PCR and RAPD typing), but no clonal relationship was observed for the remaining isolates.
The 23 isolates that contained bla KPC were highly resistant to most other antibiotic classes, including aminoglycosides, fluoroquinolones and colistin. Tigecycline was the only antibiotic active against KPC producers (95.7% susceptibility) ( Table 2 ). The bla KPC variants found in this study were those reported most commonly worldwide, namely bla KPC-3 (n¼13), bla KPC-2 (n¼8) and a new allele bla KPC-11 (n¼2) described in a previous study (C. Lascols, M. Hackel, S. H. Marshall, A. M. Hujer, D. Hoban, S. Hawser, R. Badal and R. A. Bonomo, unpublished results) (GenBank accession number HM066995). Some of the K. pneumoniae isolates additionally harboured bla ESBL , namely bla SHV-12 (n¼7) or bla CTX-M-14 (n¼3). One C. freundii isolate harboured bla SHV-12 along with bla CMY-2 and two E. cloacae harboured bla ACT/MIR ( Table 2) .
The bla KPC -positive isolates, which were from seven hospitals, comprised four different STs. Fourteen of the 18 isolates tested belonged to ST258, which is the most common clone observed among K. pneumoniae. ST258, which was found in six different hospitals in three countries (Israel, Greece and the USA) carried bla KPC-3 (n¼ 8), bla KPC-2 (n¼ 4) or bla KPC-11 (n¼ 2). Two S. marcescens isolates from the same hospital in Colombia were genetically related (cluster B by ERIC-PCR and RAPD typing) and the remaining isolates were of genetically different origins (Table 2) .
Seven bla VIM -containing isolates were identified, comprising three E. cloacae isolates carrying a bla AmpC (bla ACT/MIR ) and one K. pneumoniae and two C. freundii isolates associated with either an ESBL (bla or an AmpC (bla CMY-2 ), respectively, and one K. pneumoniae isolate harbouring both bla SHV-31 and bla DHA (Table 3 ). The only antibiotic active against bla VIMharbouring (n¼ 7) and bla OXA-48 -harbouring (n¼ 3) isolates remained tigecycline, with 85.7% and 100% susceptibility, respectively, at the FDA susceptibility breakpoint of ≤2 mg/L. Isolates carrying bla OXA-48 were always associated with bla CTX-M-15 , and in two cases were additionally associated with bla NDM-1 . All bla VIM -containing isolates possessed a bla VIM-1 -like gene except for one E. cloacae isolate that carried a bla VIM-5 -like gene. Two C. freundii bla VIM -possessing isolates demonstrated identical ERIC-PCR and RAPD profiles (cluster C) and were detected in the same hospital emergency room (Italy). The three K. pneumoniae bla OXA-48 -possessing strains belonged to multilocus STs ST43, ST147 and ST258, and there was no genetic link among these isolates.
The diversity, in these bla NDM-1 -containing isolates, of both the b-lactamase genes and the range of genera and species is consistent with the findings of Kumarasamy et al. Lascols et al.
Conclusions
Pathogens that produce carbapenemases along with an ESBL or AmpC b-lactamases are particularly challenging for clinicians and are a major threat worldwide. This is an alarming public health concern since carbapenemase-containing isolates are highly resistant to most antibiotic classes, even including colistin and tigecycline in some bla NDM-1 -containing isolates. Unfortunately, new and effective antibiotics are currently still not available. Moreover, the widespread dissemination of the new NDM-1 metallo-b-lactamase requires particular attention as the genetic background demonstrates extreme mobility and versatility. Carbapenemases are becoming a worrisome global problem, and molecular epidemiological studies will be important in determining, tracking and better understanding the dissemination of these plasmid-mediated enzymes.
